You are here: Industry Insights > Sp

News List

Global Shingles (Herpes Zoster) Market Trends and Prospects David Orchard-Webb
March 18, 2025
The global shingles market is growing due to factors like an aging population. It elaborates on drivers, segmentation, competition, and future trends.
The Global Alpha-Glucosidase Inhibitor Market: Trends and Prospects David Orchard-Webb
March 18, 2025
Alpha-glucosidase inhibitors are used for type 2 diabetes. This article analyzes their market, including growth, segments, and challenges.
Microbiome Impact on Drug Response and Personalized Medicine Nurah Ekhlaque
February 18, 2025
The gut microbiome impacts drug response and disease management. It affects drug metabolism, efficacy, and toxicity, and is crucial for personalized medicine.
Which ADCs Are Favored by Global Companies in 2024? 2 Bispecific ADCs, 5 Transactions Exceeding USD 1 Billion Yi
January 23, 2025
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
Leading the Development of Bispecific ADCs, Multiple Chinese New Drugs Go Global Yi
December 20, 2024
On November 18, it was announced that VelaVigo has entered into a global strategic cooperation agreement with Avenzo Therapeutics.
Future Prospects of Small Molecule and Monoclonal Antibody Drugs in Oncology and Immunology Krebs Qin
October 18, 2024
Specifically, there is a balance between small molecules and monoclonal antibody drugs (mAbs) in the realm of oncology super blockbuster drugs, while immunology appears dominated by monoclonal antibodies and protein-based treatments.
What Sparks Will Come from the Collaboration Between CSPC and AstraZeneca? wan
October 18, 2024
On October 7, 2024, CSPC Pharmaceutical Group Co., Ltd entered into a significant collaboration agreement with AstraZeneca, creating quite a stir in the pharmaceutical industry.
Antabio Announces Successful Completion of Phase 1 Clinical Study of MEM-ANT3310 for Severe Hospital Infections PharmaSources
October 14, 2024
Antabio’s MEM-ANT3310 is a next generation broad-spectrum antibacterial combination that has been designed to address the growing problem of antimicrobial resistance in severe hospital infections.
Navigating the Landscape of Rare Diseases: Current Trends and Future Perspectives Neeta Ratanghayra
September 29, 2024
Rising Investment and Market Dynamics, Future Perspectives in the Orphan Drug Market and The Scenario in China.
The Global Vitamin E Market: Current Trends and Future Prospects David Orchard-Webb
August 01, 2024
The global vitamin E market is poised for significant growth in the coming years.